Developer docs
API playgroundTry for free, no card

Search company profiles

Tissue Dynamics

Full company profile

uuid0004h8y

Namestring
Tissue Dynamics
Legal namestring
Tissue Dynamics
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Tissue Dynamics is a private Israeli biotechnology company founded in 2017 and headquartered in Rehovot, Israel, with a European office in Paris. The company builds an AI-powered organ-on-a-chip platform that combines human organoids with embedded metabolic sensors and high-throughput robotic automation to generate human-relevant preclinical data for drug discovery and toxicity assessment, primarily serving pharmaceutical and biotechnology research teams.

The company's core offering is the Bionic Discovery Platform, which integrates three proprietary technology layers: DynamiX, a sensor platform providing real-time readout of organoid metabolism and function under physiological conditions; MechaniX, an AI software suite that reconstructs metabolic networks and process dynamics, identifies novel targets, and claims to predict human-relevant toxicity with over 95% accuracy; and a robotic automation platform that forms, tracks, and studies over 20,000 human organoids in parallel. Complementing the platform are four service lines — Compound Profiling & Screening, Model & Assay Development, Drug Development Partnerships, and Safety Pharmacology & Toxicology — delivered through custom-engagement, project-based contracts. Scientific credibility is supported by publications in Nature, eLife, and Science Translational Medicine, and the team includes Nobel laureate Roger Kornberg (Stanford) and former TEVA CEO Erez Vigodman as advisors.

Tissue Dynamics operates a B2B professional services model, generating revenue through collaborative drug development partnerships, custom assay development, compound screening, and safety/toxicology engagements with pharma and biotech clients. Pricing is not publicly disclosed and is structured as bespoke project quotes rather than standardized list pricing. The go-to-market relies on scientific publications, peer-reviewed case studies, and direct scientific-team engagement rather than traditional sales channels, targeting enterprise R&D buyers. The company's only named strategic partnership is with Galmed Pharmaceuticals (announced 2026-05-06) for a cardiac fibrosis program combining Aramchol-based therapeutics with the organoid platform.

Short descriptiontext

Tissue Dynamics is a private Israeli biotechnology company that builds an AI-powered organ-on-a-chip platform combining human organoids, embedded metabolic sensors, and high-throughput robotic automation to deliver human-relevant drug discovery and toxicology screening services to pharmaceutical and biotech R&D teams.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ-on-chip platform, drug toxicity screening, human organoid models, preclinical drug testing, AI drug discovery
Industry3 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Preclinical Drug Development Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development Services
TypeProfessional Services
Description

Revenue generated through service contracts including compound profiling and screening, model and assay development, safety pharmacology and toxicology assessment, and collaborative drug development partnerships. Services are offered to pharmaceutical and biotech companies seeking human-relevant drug discovery data.

tissuedynamics.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Tissue Dynamics develops and operates an AI-powered organ-on-a-chip platform that combines human organoids with embedded metabolic sensors, robotic automation, and AI analysis to deliver human-relevant drug toxicity, efficacy, and mechanism-of-action data. The company sells preclinical drug development services to pharmaceutical and biotechnology companies, including compound profiling, custom assay development, safety pharmacology/toxicology assessment, and collaborative drug development partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Fourfold reduction in fibrotic burden while maintaining cardiac function in preclinical cardiac fibrosis studies
+1 more record
Product overview1 text field

Tissue Dynamics offers a unified Bionic Discovery Platform combining DynamiX (real-time metabolic sensor technology), MechaniX (AI-powered metabolic network reconstruction software), and high-throughput robotic automation capable of studying over 20,000 human organoids in parallel. The platform is complemented by four service offerings: Compound Profiling & Screening, Model & Assay Development, Drug Development Partnerships, and Safety Pharmacology & Toxicology. The DynamiX platform provides real-time metabolic readouts while MechaniX employs AI to reconstruct metabolic networks and predict human-relevant toxicity with over 95% accuracy.

Product and service7 records
1Bionic Discovery Platform
CategoryCore Technology Platform
Description

Massively scalable organ-on-a-chip platform combining embedded metabolic sensors, AI analysis, and high-throughput robotic automation for human-relevant drug discovery and toxicity prediction, sold to pharmaceutical and biotechnology companies.

2DynamiX
CategorySensor Technology Platform
Description

Advanced sensor technology platform enabling real-time readout of human organoid metabolism and function under physiological conditions, providing critical insight into disease dynamics and mechanisms for drug discovery researchers.

3MechaniX
CategoryAI Software Platform
Description

AI-powered software suite that reconstructs metabolic networks and process dynamics to identify novel drug targets, generate unique therapeutic assets, and predict human-relevant toxicity with over 95% accuracy.

4Compound Profiling & Screening
CategoryDrug Discovery Service
Description

Real-time human organoid screening service delivering unmatched functional and metabolic insights to support smarter drug development decisions for pharmaceutical and biotech clients.

5Model & Assay Development
CategoryDrug Discovery Service
Description

Custom design of organoid models with integrated biomarkers and multi-omics endpoints, providing precise mechanism-of-action and translational insights for pharmaceutical and biotech researchers.

6Drug Development Partnerships
CategoryDrug Discovery Service
Description

Collaborative service integrating human disease biology with the Tissue Dynamics scientific team to accelerate candidate validation and translation toward clinical success for pharmaceutical and biotech partners.

7Safety Pharmacology & Toxicology
CategoryDrug Discovery Service
Description

Organoid-based toxicology assessment across key human tissues, tracking tissue injury and off-target effects with continuous readouts, designed for pharmaceutical and biotech safety evaluation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Strategic collaboration to develop a novel human chronic cardiac fibrosis platform using vascularized, sensor-embedded cardiac organoids to advance Aramchol-based therapeutics for conditions including post-myocardial infarction remodeling and HFpEF. The partnership combines Tissue Dynamics' high-throughput organoid technology with Galmed's expertise in SCD1 biology and metabolic pathway modulation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Emulate is a direct organ-on-chip competitor offering its Organ-Chip platform for human-relevant disease modeling and drug toxicity testing. Both companies target pharma R&D with microphysiological systems designed to replace animal models.

TypeDirect peer
Description

Mimetas develops OrganoPlate-based organoid and organ-on-chip models for high-throughput drug screening. It directly competes with Tissue Dynamics in providing human-relevant preclinical disease models to pharmaceutical partners.

3CN Bio Innovations
TypeDirect peer
Description

CN Bio develops multi-organ microphysiological systems (e.g., PhysioMimix) for drug safety and efficacy testing. It competes head-to-head with Tissue Dynamics in organ-on-chip services aimed at pharma toxicology and disease modeling.

TypeDirect peer
Description

TissUse builds multi-organ-on-chip platforms (MOC) for systemic toxicity and efficacy testing. It is a direct competitor serving similar pharma clients with chip-based human model screening services.

TypeDirect peer
Description

InSphero provides 3D microtissue and organoid models for toxicology and disease research. It overlaps with Tissue Dynamics in human organoid-based drug discovery platforms sold to pharmaceutical R&D.

TypeEmerging player
Description

Hesperos builds multi-organ human-on-a-chip systems used in preclinical drug testing. It overlaps with Tissue Dynamics in human-relevant physiology platforms but focuses on integrated multi-organ configurations rather than high-throughput organoid scaling.

TypeEmerging player
Description

DefiniGEN provides iPSC-derived disease models and organoid services for drug discovery. It is comparable to Tissue Dynamics in supplying human cellular models to pharma and biotech for preclinical research.

TypeBroad incumbent
Description

Charles River is a major preclinical CRO offering safety pharmacology and toxicology services. It is a broad incumbent that competes with Tissue Dynamics for outsourced preclinical safety contracts and is increasingly building in vitro/organoid capabilities.

TypeBroad incumbent
Description

Cyprotex, an Evotec company, provides ADME-Tox and organ-on-chip preclinical services. It is a broad incumbent in human-relevant in vitro toxicology, comparable to Tissue Dynamics' MechaniX-enabled safety pharmacology offering.

TypeOthers
Description

Galmed is an Aramchol-focused clinical-stage pharma partner of Tissue Dynamics. While not a competitor, it is a key commercial counterpart whose ongoing collaboration validates real-world demand for Tissue Dynamics' cardiac fibrosis platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tissue Dynamics

Preclinical Drug Development Servicestissuedynamics.com

Tissue Dynamics is a private Israeli biotechnology company that builds an AI-powered organ-on-a-chip platform combining human organoids, embedded metabolic sensors, and high-throughput robotic automation to deliver human-relevant drug discovery and toxicology screening services to pharmaceutical and biotech R&D teams.

What Tissue Dynamics does

Tissue Dynamics is a private Israeli biotechnology company founded in 2017 and headquartered in Rehovot, Israel, with a European office in Paris. The company builds an AI-powered organ-on-a-chip platform that combines human organoids with embedded metabolic sensors and high-throughput robotic automation to generate human-relevant preclinical data for drug discovery and toxicity assessment, primarily serving pharmaceutical and biotechnology research teams.

The company's core offering is the Bionic Discovery Platform, which integrates three proprietary technology layers: DynamiX, a sensor platform providing real-time readout of organoid metabolism and function under physiological conditions; MechaniX, an AI software suite that reconstructs metabolic networks and process dynamics, identifies novel targets, and claims to predict human-relevant toxicity with over 95% accuracy; and a robotic automation platform that forms, tracks, and studies over 20,000 human organoids in parallel. Complementing the platform are four service lines — Compound Profiling & Screening, Model & Assay Development, Drug Development Partnerships, and Safety Pharmacology & Toxicology — delivered through custom-engagement, project-based contracts. Scientific credibility is supported by publications in Nature, eLife, and Science Translational Medicine, and the team includes Nobel laureate Roger Kornberg (Stanford) and former TEVA CEO Erez Vigodman as advisors.

Tissue Dynamics operates a B2B professional services model, generating revenue through collaborative drug development partnerships, custom assay development, compound screening, and safety/toxicology engagements with pharma and biotech clients. Pricing is not publicly disclosed and is structured as bespoke project quotes rather than standardized list pricing. The go-to-market relies on scientific publications, peer-reviewed case studies, and direct scientific-team engagement rather than traditional sales channels, targeting enterprise R&D buyers. The company's only named strategic partnership is with Galmed Pharmaceuticals (announced 2026-05-06) for a cardiac fibrosis program combining Aramchol-based therapeutics with the organoid platform.

Tissue Dynamics firmographics

Firmographics
Name
Tissue Dynamics
Legal name
Tissue Dynamics
Website
https://tissuedynamics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Tissue Dynamics is a private Israeli biotechnology company that builds an AI-powered organ-on-a-chip platform combining human organoids, embedded metabolic sensors, and high-throughput robotic automation to deliver human-relevant drug discovery and toxicology screening services to pharmaceutical and biotech R&D teams.
Ownership category
akta.pro rank

Tissue Dynamics industry classification

Industry
Product category
Preclinical Drug Development Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Organ-on-chip platform
  • Drug toxicity screening
  • Human organoid models
  • Preclinical drug testing
  • AI drug discovery

Where Tissue Dynamics is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Tissue Dynamics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Drug Development Services: Revenue generated through service contracts including compound profiling and screening, model and assay development, safety pharmacology and toxicology assessment, and collaborative drug development partnerships. Services are offered to pharmaceutical and biotech companies seeking human-relevant drug discovery data.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Tissue Dynamics product offering

Product offering

Core offering

Tissue Dynamics develops and operates an AI-powered organ-on-a-chip platform that combines human organoids with embedded metabolic sensors, robotic automation, and AI analysis to deliver human-relevant drug toxicity, efficacy, and mechanism-of-action data. The company sells preclinical drug development services to pharmaceutical and biotechnology companies, including compound profiling, custom assay development, safety pharmacology/toxicology assessment, and collaborative drug development partnerships.

Product overview

Tissue Dynamics offers a unified Bionic Discovery Platform combining DynamiX (real-time metabolic sensor technology), MechaniX (AI-powered metabolic network reconstruction software), and high-throughput robotic automation capable of studying over 20,000 human organoids in parallel. The platform is complemented by four service offerings: Compound Profiling & Screening, Model & Assay Development, Drug Development Partnerships, and Safety Pharmacology & Toxicology. The DynamiX platform provides real-time metabolic readouts while MechaniX employs AI to reconstruct metabolic networks and predict human-relevant toxicity with over 95% accuracy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bionic Discovery Platform Massively scalable organ-on-a-chip platform combining embedded metabolic sensors, AI analysis, and high-throughput robotic automation for human-relevant drug discovery and toxicity prediction, sold to pharmaceutical and biotechnology companies.
  • DynamiX Advanced sensor technology platform enabling real-time readout of human organoid metabolism and function under physiological conditions, providing critical insight into disease dynamics and mechanisms for drug discovery researchers.
  • MechaniX AI-powered software suite that reconstructs metabolic networks and process dynamics to identify novel drug targets, generate unique therapeutic assets, and predict human-relevant toxicity with over 95% accuracy.
  • Compound Profiling & Screening Real-time human organoid screening service delivering unmatched functional and metabolic insights to support smarter drug development decisions for pharmaceutical and biotech clients.
  • Model & Assay Development Custom design of organoid models with integrated biomarkers and multi-omics endpoints, providing precise mechanism-of-action and translational insights for pharmaceutical and biotech researchers.
  • Drug Development Partnerships Collaborative service integrating human disease biology with the Tissue Dynamics scientific team to accelerate candidate validation and translation toward clinical success for pharmaceutical and biotech partners.
  • Safety Pharmacology & Toxicology Organoid-based toxicology assessment across key human tissues, tracking tissue injury and off-target effects with continuous readouts, designed for pharmaceutical and biotech safety evaluation.

Quantifiable outcome

  • Fourfold reduction in fibrotic burden while maintaining cardiac function in preclinical cardiac fibrosis studies
  • +1 more outcomes

Companies that use Tissue Dynamics

Customer profile

Segments2 records

Ideal customer profiles1 record

Tissue Dynamics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Tissue Dynamics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Galmed PharmaceuticalscoreStrategic or Co-development Partner · 6 May 2026Strategic collaboration to develop a novel human chronic cardiac fibrosis platform using vascularized, sensor-embedded cardiac organoids to advance Aramchol-based therapeutics for conditions including post-myocardial infarction remodeling and HFpEF. The partnership combines Tissue Dynamics' high-throughput organoid technology with Galmed's expertise in SCD1 biology and metabolic pathway modulation.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Tissue Dynamics competitors and assessment

Company assessment

Direct peers

  • Emulate: Emulate is a direct organ-on-chip competitor offering its Organ-Chip platform for human-relevant disease modeling and drug toxicity testing. Both companies target pharma R&D with microphysiological systems designed to replace animal models.
  • Mimetas: Mimetas develops OrganoPlate-based organoid and organ-on-chip models for high-throughput drug screening. It directly competes with Tissue Dynamics in providing human-relevant preclinical disease models to pharmaceutical partners.
  • CN Bio Innovations: CN Bio develops multi-organ microphysiological systems (e.g., PhysioMimix) for drug safety and efficacy testing. It competes head-to-head with Tissue Dynamics in organ-on-chip services aimed at pharma toxicology and disease modeling.
  • TissUse: TissUse builds multi-organ-on-chip platforms (MOC) for systemic toxicity and efficacy testing. It is a direct competitor serving similar pharma clients with chip-based human model screening services.
  • InSphero: InSphero provides 3D microtissue and organoid models for toxicology and disease research. It overlaps with Tissue Dynamics in human organoid-based drug discovery platforms sold to pharmaceutical R&D.

Emerging players

  • Hesperos: Hesperos builds multi-organ human-on-a-chip systems used in preclinical drug testing. It overlaps with Tissue Dynamics in human-relevant physiology platforms but focuses on integrated multi-organ configurations rather than high-throughput organoid scaling.
  • DefiniGEN: DefiniGEN provides iPSC-derived disease models and organoid services for drug discovery. It is comparable to Tissue Dynamics in supplying human cellular models to pharma and biotech for preclinical research.

Broad incumbents

  • Charles River Laboratories: Charles River is a major preclinical CRO offering safety pharmacology and toxicology services. It is a broad incumbent that competes with Tissue Dynamics for outsourced preclinical safety contracts and is increasingly building in vitro/organoid capabilities.
  • Cyprotex (Evotec): Cyprotex, an Evotec company, provides ADME-Tox and organ-on-chip preclinical services. It is a broad incumbent in human-relevant in vitro toxicology, comparable to Tissue Dynamics' MechaniX-enabled safety pharmacology offering.

Others

  • Galmed Pharmaceuticals: Galmed is an Aramchol-focused clinical-stage pharma partner of Tissue Dynamics. While not a competitor, it is a key commercial counterpart whose ongoing collaboration validates real-world demand for Tissue Dynamics' cardiac fibrosis platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Tissue Dynamics social profiles

Digital presence

Tissue Dynamics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tissue Dynamics leadership team

Management profile

Number of profiles

Profiles4 records

Tissue Dynamics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tissue Dynamics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tissue Dynamics

What does Tissue Dynamics do?

Tissue Dynamics develops and operates an AI-powered organ-on-a-chip platform that combines human organoids with embedded metabolic sensors, robotic automation, and AI analysis to deliver human-relevant drug toxicity, efficacy, and mechanism-of-action data. The company sells preclinical drug development services to pharmaceutical and biotechnology companies, including compound profiling, custom assay development, safety pharmacology/toxicology assessment, and collaborative drug development partnerships.

Is Tissue Dynamics a public or private company?

Tissue Dynamics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Tissue Dynamics founded?

Tissue Dynamics was founded in 2017. It employs 11 to 50 people.

Where is Tissue Dynamics based?

Tissue Dynamics is headquartered in Jerusalem, Israel, in the Middle East region.

How does Tissue Dynamics make money?

One revenue line is on record: drug Development Services.

Who are Tissue Dynamics's main competitors?

Direct peers on record are Emulate, Mimetas, CN Bio Innovations, TissUse and InSphero. Emerging players are Hesperos and DefiniGEN. Broad incumbents are Charles River Laboratories and Cyprotex (Evotec). Galmed Pharmaceuticals is listed as an others.

Does Tissue Dynamics have an API?

No public API is recorded for Tissue Dynamics.

What industry is Tissue Dynamics in?

Tissue Dynamics's product category is Preclinical Drug Development Services. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac FibrosisTissue Dynamics and Galmed Pharmaceuticals announced preclinical results demonstrating that a combination of Aramchol Meglumine and a PPARα agonist reduces cardiac fibrosis in human cardiac organoid models, revealing a new metabolic pathway. The study showed a fourfold reduction in fibrotic burden while maintaining cardiac function, with preparations underway for further development. The research highlights a human-specific mechanism not accessible through animal models, aiming to develop new therapies for cardiac fibrosis.AijournTissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based TherapeuticsTissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. announced a collaboration to develop a novel human chronic cardiac fibrosis platform using vascularized, sensor-embedded cardiac organoids to advance Aramchol-based therapeutics for conditions including post-myocardial infarction remodeling and HFpEF. The platform will combine Tissue Dynamics' high-throughput organoid technology with embedded metabolic sensors and AI analysis with Galmed's expertise in SCD1 biology and metabolic pathway modulation. Cardiovascular disease caused an estimated 20.5 million deaths in 2025, and there are currently no approved therapies that directly and durably reverse cardiac fibrosis.PR NewswireTissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based TherapeuticsTissue Dynamics and Galmed Pharmaceuticals announced a collaboration to develop a human chronic cardiac fibrosis model using vascularized, sensor-embedded cardiac organoids. The platform will test over 20,000 organoids in parallel to accelerate Aramchol-based therapies for heart failure with preserved ejection fraction and post-MI remodeling.YahooATCC and Tissue Dynamics Announce a Strategic Collaboration to Bring a Transformative Heart Organoid Model to MarketATCC and Tissue Dynamics announced a partnership to develop cardiac organoid-based kits for cardiac safety testing, under a two-year BIRD grant. The collaboration aims to advance the multi-chambered cardiac organoid model for industrial use, addressing drug-induced cardiotoxicity.PR NewswireProf. Roger D. Kornberg, Chemistry Nobel laureate, will be joining Tissue Dynamics' advisory boardTissue Dynamics, an Israeli AI/ML biopharma company, announced on May 31, 2023 that Nobel laureate Roger D. Kornberg, a Stanford structural biology professor, will join its advisory board. Kornberg, known for work on transcription, previously advised Pacific Biosciences and Teva Pharmaceuticals. The company's DynamiX platform uses human-on-chip models and AI/ML algorithms for drug discovery.PR NewswireTissue Dynamics Unveiling DynamiX® a Bionic Multi Organ-on-Chip BioanalyzerTissue Dynamics unveiled DynamiX, a bionic multi organ-on-chip bioanalyzer capable of communicating with sensors embedded in living human microtissues while mimicking human physiological conditions. The platform addresses the long-standing reliance on animal models in drug development, which contributes to over 88% of clinical trial failures due to species differences in metabolism and physiology. The technology, developed in 2015 and previously used by pharmaceutical companies for cancer, metabolic disease, and viral infection research, integrates real-time metabolic sensors and automation to generate thousands of human-relevant data points per experiment.